Back to Treatments

Treatment

Cemiplimab

1
Conditions
7
Trials
2,000
Participants
40%
Average Safety

Condition Evidence

Non-melanoma skin cancer (squamous-cell carcinoma)

7 trials · 2,000 participants

88% effectiveness · 40% safety
Cemiplimab | DFDA